Acrivon (ACRV, Financial) reported significant strides in the first quarter, focusing on enhancing its clinical pipeline and expanding its Generative Phosphoproteomics AP3 capabilities. The company also bolstered its leadership team. During a recent R&D event, Acrivon presented updated interim data from its ongoing ACR-368 Phase 2b trial in endometrial cancer patients. This study targets those with large and aggressive tumors who have not responded to previous platinum-based chemotherapy and anti-PD-1 treatments. The results underscore the potential to fulfill an unmet need for second-line therapies and to expand treatment labels with ACR-368 as a switch maintenance option through a confirmatory trial.
In addition, ACR-2316, Acrivon's second clinical-stage product, demonstrated promising tumor reduction in a patient with a significant metastatic burden within six weeks at dose level 3, suggesting its potential as a monotherapy. The company is also excited to announce that Dr. Mansoor Raza Mirza, a respected oncologist, has joined as Chief Medical Officer, bringing extensive expertise to guide the development of Acrivon's pipeline.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Acrivon Therapeutics Inc (ACRV, Financial) is $11.50 with a high estimate of $19.00 and a low estimate of $6.00. The average target implies an upside of 908.77% from the current price of $1.14. More detailed estimate data can be found on the Acrivon Therapeutics Inc (ACRV) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Acrivon Therapeutics Inc's (ACRV, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
